BlueWind Medical Announces Humana Coverage of Revi® for Urgency Urinary Incontinence, Expanding Access to Millions of Patients

SALT LAKE CITY--(BUSINESS WIRE)--BlueWind Medical, a leader in Implantable Tibial Neuromodulation (ITNM) and developer of the Revi^® System, a patient-centric solution for urgency urinary incontinence (UUI), today announced that Humana will provide coverage for implantable tibial neuromodulation therapy for the treatment of UUI, including the Revi System, effective October 1, 2026.

Humana is the second-largest Medicare Advantage organization in the U.S., with approximately 11 million enrollees in 2026.¹

Designed for a 15-year implant life, the miniature device is placed near the ankle in an outpatient procedure under local anesthesia. Patients receive personalized therapy at home that is powered using a lightweight external wearable transmitter.

“Humana's decision represents an important milestone for patients living with urgency urinary incontinence and for the continued advancement of implantable tibial neuromodulation,” said Kerry Nelson, CEO of BlueWind Medical. “For years, BlueWind has been committed to advancing the clinical evidence needed to demonstrate the value of the subfascial tibial approach and to expand access to this less invasive, highly effective technology. We are proud that the growing body of evidence, including three-year data from our pivotal OASIS study showing 95% patient satisfaction, has helped support greater recognition of this treatment option.”

BlueWind has played a leading role in advancing the clinical evidence supporting implantable tibial neuromodulation. The company's pivotal OASIS study provides three-year data demonstrating durable improvements in urgency urinary incontinence symptoms, with 79% of participants achieving at least 50% improvement and 63% achieving at least 75% improvement. In its updated Medicare Advantage medical coverage policy, Humana cites the OASIS study among the evidence supporting its coverage determination for implanted posterior tibial nerve stimulation.

Additionally, Revi is differentiated by its subfascial implant placement, positioning the miniature device in close proximity to the tibial nerve. Last week, BlueWind also announced that the American Medical Association (AMA) CPT® Editorial Panel approved a new Category I CPT code for subfascial implantation of a tibial neuromodulation device.

About the Revi System

The Revi® System is an FDA-approved tibial neuromodulation treatment for urgency urinary incontinence. Its miniature implant is placed near the ankle and powered by a lightweight external wearable that patients use to receive personalized therapy at home. Designed for a 15-year implant life, Revi avoids the need for implanted battery replacements and repeated office visits for routine treatment.

About BlueWind Medical

BlueWind Medical is a medical device company focused on advancing treatment for urgency urinary incontinence. Through the Revi System, the company aims to provide durable symptom relief with a simple implantation procedure and personalized therapy that fits into patients’ daily lives. For more information, visit https://bluewindmedical.com/.

References:
1. Covered lives information provided by MMIT, AIS Directory of Health Plans, 3Q 2025.
2. Link to Humana Policy.